Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus

Launched by UNIVERSITY HOSPITAL, TOURS · May 12, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain immune cells behave in patients with systemic lupus erythematosus (commonly known as lupus). Specifically, researchers are looking at the expression of a receptor called the neonatal Fc receptor (FcRn) in special immune cells known as Natural Killer T cells, as well as in monocytes. They want to see how these receptors differ in active lupus patients compared to those whose lupus is inactive. This information could help scientists understand more about how lupus affects the body and possibly lead to better treatments in the future.

To participate in this study, you need to be at least 18 years old and have been diagnosed with lupus, either recently or in the past. You can be untreated or experiencing a relapse, but your doctor must consider you stable enough for the study. The trial is currently recruiting participants, and all genders are welcome. If you join, you can expect to provide blood samples, which will help the researchers gather the information they need to learn more about lupus. Remember, this study is designed to advance our understanding of lupus, so your contribution could be very valuable!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and/or secondary Gougerot-Sjögren's
• • Lupus patient, newly diagnosed or known, untreated or in relapse
• • Lupus patient considered stable by the treating practitioner
• • Requiring blood sampling for follow-up
• Exclusion Criteria:
• • Main autoimmune disease other than lupus
• • Patient under legal protection, guardianship or curators
• • Opposition to data processing